Literature DB >> 33098033

Neurolymphomatosis: a single-center experience of neuromuscular manifestations, treatments, and outcomes.

Jisun Jeong1, Sun Woong Kim1, Duk Hyun Sung2.   

Abstract

OBJECTIVES: Neurolymphomatosis (NL) is a disease characterized by the infiltration of malignant lymphocytes into the peripheral nervous system. We report clinical features, radiographic findings, modes of treatment, and outcomes of patients with NL.
METHODS: We retrospectively investigated patients with NL. We extracted data, including clinical features, magnetic resolution imaging (MRI), 18F-fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scans, cerebrospinal fluid cytology findings, the results of electrodiagnostic studies, as well as patient treatments and outcomes.
RESULTS: Ten NL patients were identified. All patients reported pain/paresthesia and weakness in the affected area. The MRI scans were abnormal in eight out of nine patients with an enhancement of the spinal nerve root, plexus, peripheral nerve trunk, and cranial nerve. The FDG PET/CT scans were positive in all patients. Radiculopathy or radiculoplexopathy was the most common electrodiagnostic finding. Neurological improvement was observed in only three patients. The condition of the nine patients who underwent multimodality treatments for cancer eventually deteriorated and the patients died.
CONCLUSIONS: NL should be considered in the differential diagnosis of any type of neuropathy in patients with lymphoma. Because it could be confused with other neuropathies in lymphoma and various musculoskeletal diseases, a high index of suspicion and familiarity with clinical manifestation of NL are key. FDG PET/CT was the most sensitive diagnostic imaging modality to detect relevant neural invasion. The root within the spinal neural foramen was the most frequently affected neural structure. Early diagnosis of this rare neurologic manifestation of lymphoma may improve treatment outcomes.

Entities:  

Keywords:  FDG-PET/CT; Lymphoma; MRI; Neurolymphomatosis; Peripheral nervous system

Mesh:

Substances:

Year:  2020        PMID: 33098033     DOI: 10.1007/s00415-020-10202-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

Authors:  Sigal Grisariu; Batia Avni; Tracy T Batchelor; Martin J van den Bent; Felix Bokstein; David Schiff; Outi Kuittinen; Marc C Chamberlain; Patrick Roth; Anatoly Nemets; Edna Shalom; Dina Ben-Yehuda; Tali Siegal
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

2.  Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.

Authors:  Hui K Gan; Arun Azad; Lawrence Cher; Paul L R Mitchell
Journal:  Neuro Oncol       Date:  2009-12-24       Impact factor: 12.300

3.  Neurolymphomatosis: MRI and (18) FDG-PET features.

Authors:  Anthony Tien Hoe Lim; Danielle Clucas; Christine Khoo; Bimal Kumar Parameswaran; Eddie Lau
Journal:  J Med Imaging Radiat Oncol       Date:  2015-05-13       Impact factor: 1.735

Review 4.  Diagnosis and management of neurolymphomatosis.

Authors:  Joachim M Baehring; Tracy T Batchelor
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

5.  Neurolymphomatosis.

Authors:  Joachim M Baehring; Denise Damek; Emily C Martin; Rebecca A Betensky; Fred H Hochberg
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

6.  Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience.

Authors:  Ja Min Byun; Ki Hwan Kim; Miso Kim; Tae Min Kim; Yoon Kyung Jeon; Jeong Hwan Park; Jin Ho Paik; Jung Min Lee; Ho-Young Lee; Jong Seok Lee; Dae Seog Heo; Jeong-Ok Lee
Journal:  Leuk Lymphoma       Date:  2017-05-09

7.  Neurolymphomatosis: a case series of clinical manifestations, treatments, and outcomes.

Authors:  Carlos Kamiya-Matsuoka; Sheetal Shroff; Kasey Gildersleeve; Bahram Hormozdi; John T Manning; Karin H Woodman
Journal:  J Neurol Sci       Date:  2014-06-02       Impact factor: 3.181

8.  Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?

Authors:  K Viala; A Béhin; T Maisonobe; J-M Léger; T Stojkovic; F Davi; V Leblond; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-10-30       Impact factor: 10.154

9.  Neurolymphomatosis: a clinicopathologic syndrome re-emerges.

Authors:  R Diaz-Arrastia; D S Younger; L Hair; G Inghirami; A P Hays; D M Knowles; J G Odel; M R Fetell; R E Lovelace; L P Rowland
Journal:  Neurology       Date:  1992-06       Impact factor: 9.910

Review 10.  Effects of lymphoma on the peripheral nervous system.

Authors:  R A Hughes; T Britton; M Richards
Journal:  J R Soc Med       Date:  1994-09       Impact factor: 18.000

View more
  2 in total

1.  Update on benign paroxysmal positional vertigo.

Authors:  Hyo-Jung Kim; JaeHan Park; Ji-Soo Kim
Journal:  J Neurol       Date:  2020-11-24       Impact factor: 4.849

2.  Neuralgic Amyotrophy as the First Presentation of Lymphoma.

Authors:  Hiroaki Yaguchi; Keisuke Yamaguchi; Yasunori Mito; Yasutaka Tajima
Journal:  Intern Med       Date:  2021-06-05       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.